<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-9933</journal-id>
<journal-title><![CDATA[Revista Información Científica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. inf. cient.]]></abbrev-journal-title>
<issn>1028-9933</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas Guantánamo]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-99332018000200307</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Índice predictivo de la anticoagulación con antagonistas de la vitamina K]]></article-title>
<article-title xml:lang="en"><![CDATA[Predictive index of the anticoagulant with antagonists of the vitamin K]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mena Bouza]]></surname>
<given-names><![CDATA[Yusmila Zerelda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estevan Soto]]></surname>
<given-names><![CDATA[José Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Elías Sierra]]></surname>
<given-names><![CDATA[Reinaldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Elias Armas]]></surname>
<given-names><![CDATA[Karla Sucet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández Betancourt]]></surname>
<given-names><![CDATA[Yamil]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Docente &#8220;Dr. Agostinho Neto"  ]]></institution>
<addr-line><![CDATA[ Guantánamo]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Facultad de Ciencias Médicas  ]]></institution>
<addr-line><![CDATA[ Guantánamo]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<volume>97</volume>
<numero>2</numero>
<fpage>307</fpage>
<lpage>314</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-99332018000200307&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-99332018000200307&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-99332018000200307&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  se recomienda la predicción del riesgo de sangrado durante la anticoagulación terapéutica.  Objetivo:  diseñar un modelo predictivo del control de la anticoagulación en pacientes tratados con warfarina sódica.  Método:  se realizó un estudio explicativo y prospectivo en 50 pacientes tratados con warfarina sódica en el Hospital General Docente &#8220;Dr. Agostinho Neto&#8221; durante el período 2015-2016. Estos se agruparon en un grupo control (n=25, aquellos con adecuada anticoagulación, INR entre 2.0-3.0) y un grupo estudio (n=25, con inadecuada anticoagulación, INR &lt; 2.0).  Resultados:  Los factores más predictivos del efecto anticoagulante insatisfactorio fueron: vivir solo y el uso de fármacos que interfieren con más constancia e intensidad en el efecto del fármaco.  Conclusiones:  se diseñó un modelo predictivo del control de la anticoagulación con warfarina, ajustado a los servicios del Hospital &#8220;Dr. Agostinho Neto&#8221;.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  it recommends the prediction of the risk of bleeding during the therapeutic anticoagulation.  Objective:  design a predictive model of the control of the anticoagulant in patients treated with warfarina sódica.  Method:  it realised an explanatory and prospective study in 50 patients treated with warfarina sódica in the Educational General Hospital &#8220;Dr. Agostinho Neto&#8221; during the period 2015-2016. These grouped in a group control (n=25, those with suitable anticoagulation, INR between 2.0-3.0) and a group study (n=25, with unsuitable anticoagulation, INR &lt; 2.0).  Results:  The most predictive factors of the effect unsatisfactory anticoagulant were: live alone and the use of drugs that interfere with more proof and intensity in the effect of the drug.  Conclusions:  it designed a predictive model of the control of the anticoagulation with warfarina, adjusted to the services of the Hospital &#8220;Dr. Agostinho Neto&#8221;]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[anticoagulación]]></kwd>
<kwd lng="es"><![CDATA[warfarina sódica]]></kwd>
<kwd lng="es"><![CDATA[antagonistas de la vitamina k]]></kwd>
<kwd lng="en"><![CDATA[anticoagulant]]></kwd>
<kwd lng="en"><![CDATA[warfarina sódica]]></kwd>
<kwd lng="en"><![CDATA[antagonists of the vitamin k]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apixaban versus warfarin in patients with atrial fibrillation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>981-2</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Hacke]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rivaroxaban versus warfarin in nonvalvular atrial fibrillation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>883-91</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Yousef]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[7004-3 - Score same-tt2r2 alto y eventos mayores adversos en pacientes anticoagulados por fibrilación auricular no valvular]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Llisterri]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso del tratamiento antitrombótico según la escala CHA 2DS2-VASc en los pacientes con fibrilación auricular]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2014</year>
<volume>67</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>150-1</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso del tratamiento antitrombótico en pacientes con fibrilación auricular en atención primaria]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2014</year>
<volume>67</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>419-23</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pueo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Anguita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Worner]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿La clasificación CHA2DS2-VASc selecciona a los pacientes que van a beneficiarse de la anticoagulación?]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2014</year>
<volume>67</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>417-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Andreotti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Arnesen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Airaksinen]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cuisset]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of antithrombotic therapy in atrial fibrillation patients]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2010</year>
<volume>103</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-28</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dans]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wallentin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamya]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brueckmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>127</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>634-40</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mega]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Bassand]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatt]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rivaroxaban in patients with a recent acute coronary syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>366</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-19</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kilaru]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Mohan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apixaban with antiplatelet therapy after acute coronary syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>365</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>699-708</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarafoff]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Martischnig]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wealer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mehilli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sibbing]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triple therapy with aspirin, prasugrel, and vitamin k antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2012</year>
<volume>61</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2060-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubois]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
<name>
<surname><![CDATA[Casal]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[OD]]></given-names>
</name>
<name>
<surname><![CDATA[Albiñana]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigo]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reticencia a adoptar las recomendaciones de tratamiento antitrombótico en la fibrilación auricular no valvular]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oldgren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Budaj]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Khder]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Siegbahn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dabigatran in patients with acute coronary syndromes]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2011</year>
<volume>32</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2781-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Schotten]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Savelieva]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guías de práctica clínica para el manejo de la fibrilación auricular]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2010</year>
<volume>63</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>14-83</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bertomeu]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bertomeu]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto de los nuevos criterios para el tratamiento anticoagulante de la fibrilación auricular]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2011</year>
<volume>64</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>649-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
